Compare UGI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGI | PRAX |
|---|---|---|
| Founded | 1940 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.3B |
| IPO Year | 1994 | 2020 |
| Metric | UGI | PRAX |
|---|---|---|
| Price | $37.17 | $238.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $43.25 | ★ $644.42 |
| AVG Volume (30 Days) | ★ 1.7M | 482.6K |
| Earning Date | 11-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 147.20 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $7,287,000,000.00 | N/A |
| Revenue This Year | $0.79 | N/A |
| Revenue Next Year | $5.55 | $39,458.00 |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $31.65 | $154.46 |
| 52 Week High | $41.34 | $392.70 |
| Indicator | UGI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 22.00 |
| Support Level | $36.93 | $238.77 |
| Resistance Level | $37.58 | $356.02 |
| Average True Range (ATR) | 0.68 | 12.12 |
| MACD | 0.09 | -3.04 |
| Stochastic Oscillator | 70.66 | 4.26 |
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.